Quality of life and Satisfaction With Ospemifene for Treating Vulvovaginal Atrophy in Breast Cancer Survivors: Six-Month Results From the PatiEnt SatisfactiON StudY (PEONY).

Objective: Breast cancer (BC) survivors often experience vulvovaginal atrophy (VVA) due to endocrine therapies, affecting quality of life (QoL) and well-being. We aimed to evaluate impact of ospemifene treatment in postmenopausal women with history of BC and moderate to severe VVA.

Methods: PEONY is a real-world, prospective, multicenter study.

Screening tool for the identification of relative energy deficiency in Sport risk: validation of the low energy availability in female questionnaire - Italian version (LEAFQ-ITA).

Background: Relative Energy Deficiency in Sports (REDs) is defined as a multifactorial syndrome of impaired physiological and/or psychological functioning was previously named as the Female Athlete Triad. REDs was proposed to be an expansion of the Female Athlete Triad model (), corresponding to a combination of Low Energy Availability (LEA), alteration of the menstrual cycle and bone health. could be made possible by a screening tool to determine the risk of LEA.

Major adverse cardiovascular events risk in menopausal women treated with oral estradiol/micronized progesterone versus conjugated estrogens/medroxyprogesterone: a claims data analysis in the USA.

Objective: Using real-world data, the current study compared the risk of major adverse cardiovascular events (MACE) between two regulated combined oral hormonal products that are currently available to women in the USA: body-identical oral 17β-estradiol/micronized progesterone (E2/P4) and conjugated equine estrogens/medroxyprogesterone acetate (CEE/MPA).

Methods: Women aged ≥40 years treated with E2/P4 or CEE/MPA were selected from a US claims database (April 2019-June 2021). The E2/P4 or CEE/MPA cohorts were defined based on the first dispensation of E2/P4 or CEE/MPA (index) as prescribed in the real world.

PERCEIVE: A retrospective, qualitative interview-based study of the impact of vasomotor symptoms associated with menopause on the lives of individuals who are not suitable candidates for hormone therapy.

Objectives: PERCEIVE collected insights from individuals for whom menopausal hormone therapy was unsuitable for addressing the effects and management of menopausal vasomotor symptoms.

Study Design: Interviews were conducted with participants exiting DAYLIGHT (NCT05033886), a phase 3b trial of fezolinetant. DAYLIGHT enrolled menopausal women aged 40-65 years who sought relief from moderate to severe vasomotor symptoms but had contraindications/precautions to, prior discontinuation of, or aversion to using hormone therapy.

Sexual function after menopause: the role of vaginal estrogens.

Sexual health and well-being are challenged by the biopsychosocial changes associated with menopause. Local estrogen therapy (LET) represents the mainstay of managing genitourinary syndrome of menopause (GSM). However, most studies have investigated the role of LET on signs and symptoms of vulvovaginal atrophy (VVA) without fully capturing the sexual cluster of symptoms that makes women vulnerable to sexual dysfunction.

Functional hypothalamic amenorrhea and dietary intervention: A systematic review to guide further research in amenorrheic women without overt eating disorder.

Functional hypothalamic amenorrhea (FHA) is a multifactorial condition caused by psychological stress, energy deficit, weight loss, and excessive physical activity in the absence of adequate energy intake. Nutrition plays a key role in FHA treatment, with the primary intervention focused on correcting energy imbalance. Evidence regarding the exact amount of energy required to restore menses, the timeframe for recovery, and the optimal nutritional practices to support long-term recovery and optimize reproductive outcomes, remain limited.

Vulvar Care: Reviewing Concepts in Daily Hygiene.

Vulvar hygiene is an important part of general hygiene: the goals are to clear the vulvar area of microbial and cellular debris and vaginal and fecal secretions, ensure local comfort, provide natural levels of hydration, and protect the vulvar microbiota. There are few national and international guidelines on vulvar hygiene. We searched the PubMed database up until 30 November 2024, using logical combinations of the following terms: hygiene, washing, vulva, vulvar, microbiota, hydration, syndet, soap, detergent, water, and customs.

Targeting vasomotor symptoms with the new drug fezolinetant - an expert overview.

Menopause is an inevitable event in the life of women who live long enough to reach this milestone. The experience of menopause varies amongst individuals. Menopause has a negative impact on women's life and is associated with symptoms including vasomotor symptoms (VMS), such as hot flushes and night sweats, sleep disturbances and low mood.

The Role of Vaginal Oestrogen Therapy in Postmenopausal Women With Pelvic Organ Prolapse: Does It Have Any Impact on Perioperative Outcomes? A Systematic Review of Randomised Controlled Trials.

Background: Pelvic organ prolapse (POP) affects up to 50% of postmenopausal women, negatively impacting sexual function and quality of life. While surgery remains the primary treatment, increasing attention has been given to perioperative vaginal oestrogen therapy and its potential impact on surgical outcomes.

Objectives: This systematic review aims to evaluate the latest evidence on the role of vaginal oestrogen therapy in perioperative management and its impact on surgical outcomes in postmenopausal women with POP.

Persistent gaps in menopause care: current recommendations of the POESIT group.

In recent years, menopause awareness has been increasing in several European countries; however, gaps in menopause knowledge, attitudes and practices persist. This review provides an overview of the women's current menopausal experience in Italy, Spain and Portugal, and gives POESIT (Portugal + Spain + Italy) group recommendations to address persistent barriers in menopause care. The perception, occurrence and impact of menopause symptoms vary among countries, with genitourinary syndrome of menopause and vasomotor symptoms being the most frequent overall.

Do Italian ObGyn Residents Have Enough Knowledge to Counsel Women About Nutritional Facts? Results of an On-Line Survey.

: Nutrition plays a key role in gynecologic conditions, pregnancy, and perinatal outcomes; therefore, nutritional counseling is essential in obstetric and gynecologic care. The present study aimed to delineate Italian Obstetrics and Gynecology (ObGyn) residents' awareness of women's nutrition and supplementation in different stages of life. : We conducted a cross-sectional online survey about women's nutrition and supplementation use throughout their lifetime.

Bringing sex back into the relationship in midlife couples.

Sexual health and sexual well-being are important components of the overall quality of life at midlife, a turning point carrying several biopsychosocial changes. As people age, they are likely to observe a significant increase in sexual difficulties in both sexes affecting every domain of sexual response, and a decline in the frequency of engaging in sexual activity. Women may report hypoactive sexual desire disorder (HSDD) and genitourinary syndrome of menopause (GSM), two very common biologically driven midlife conditions that are often comorbid and may also be influenced by a multitude of individual and contextual risk factors.

A profile of safety and efficacy of fezolinetant for the treatment of menopausal vasomotor symptoms.

Introduction: Fezolinetant is a first-in-class non-hormonal pharmacological treatment recently approved for moderate-to-severe vasomotor symptoms (VMS) associated with menopause. Its mechanism of action selectively targets the pathophysiology of VMS at hypothalamic level, antagonizing binding of neurokinin B, overexpressed in estrogen deprived menopausal women, to the neurokinin 3 receptor (NK3R) in the thermoregulatory center.

Areas Covered: Fezolinetant reduced VMS frequency and severity in phase 3 randomized placebo-controlled trials in healthy menopausal women (SKYLIGHT 1 and 2) and in women unsuitable for menopause hormone therapy (MHT) (DAYLIGHT).

HPV-51 or HPV-52 Infection Could Impair Sperm Quality in Infertile Patients: A Preliminary Study on Our Experience from North-Western Italy.

Human papillomavirus (HPV) infection is one of the most common sexually transmitted infections in all genders worldwide. Its association with male infertility is deeply investigated, although there are conflicting data on the role of the virus in the impairment of semen quality and reduced reproductive outcomes. In this study, we considered 335 semen samples of males (age: 37.

Impact of Obesity on Pubertal Timing and Male Fertility.

Childhood obesity has profound effects on puberty in boys and girls, altering its timing, progression, and associated hormonal changes. Also, later male fertility could be impaired by childhood and pubertal obesity in light of the impact of inflammatory markers on semen quality. The aim of this narrative review is to explore the intricate relationship between childhood obesity and its impact on pubertal development and fertility, with a specific focus on boys.

Treating VVA improves symptom severity and patient-reported outcomes: 6-month PEONY results.

Objective: The real-world PatiEnt satisfactiON studY (PEONY) involves postmenopausal women already treated or starting local estrogen therapy (LET) or ospemifene. The aim of the present analysis was to assess treatment satisfaction and persistence, effectiveness and patient-reported outcomes (PROs) in sexual function and quality of life after 6 months of therapy with LET or ospemifene to treat vulvovaginal atrophy (VVA).

Methods: PEONY is an ongoing prospective, observational study conducted in 17 gynecology centers.

IVF cycle safety when a positive passive air sampling occurs under laminar flow hood in absence of a detectable contamination in the embryo culture.

Microbiological contamination in the embryo culture media might affect embryo early development and clinical outcomes during IVF procedures. Infections in the genital tract represent the most common causes of culture contamination, but also environmental air quality might have a detrimental effect on reproductive outcomes of infertile couples undergoing IVF procedures. Monitoring microbiological contamination in an embryology laboratory is mandatory and daily tests are performed under laminar vertical flow hood.

Signs and symptoms of vulvovaginal atrophy (VVA) in clinical practice - the possible involvement of thyroid autoimmunity in genitourinary syndrome of menopause (GSM).

Background: Thyroid autoimmune disorders (ADs) are common in midlife women and can impact various aspects of health, including sexual function. The effect of thyroid autoimmunity on the clinical manifestations of vulvovaginal atrophy (VVA) remains unclear.

Objective: To explore the relationship between thyroid ADs and VVA signs and symptoms in a sample of postmenopausal women.

Framing and Management of Migraines in Women: An Expert Opinion on Challenges, Current Approaches, and Future Multidisciplinary Perspectives.

Migraines are a common neurological disorder that significantly impact women, especially during their reproductive years. Hormonal, neurological, and lifestyle factors shape migraine patterns, with fluctuations during menstruation, pregnancy, perimenopause, and menopause influencing migraine prevalence and severity. This expert opinion explores current challenges, therapeutic strategies, and future directions for personalized care, addressing the limited inclusion of women in clinical research across different life stages.

Effect of fezolinetant on patient-reported quality-of-life outcomes: Data from a phase 3b study (DAYLIGHT) of the treatment of moderate to severe vasomotor symptoms associated with menopause in women considered unsuitable for hormone therapy.

Objective: To report patient-reported quality-of-life (QOL) outcomes in the DAYLIGHT study.

Study Design: DAYLIGHT was a phase 3b, randomized, double-blind, 24-week, placebo-controlled study. Participants were women aged ≥40 to ≤65 years with moderate to severe vasomotor symptoms (VMS) considered unsuitable for hormone therapy (HT) (contraindications, caution, stoppers, or averse) randomized 1:1 to placebo or fezolinetant 45 mg once daily.